🇺🇸 FDA
Patent

US 7378097

Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant

granted A61KA61K2039/53A61K2039/54

Quick answer

US patent 7378097 (Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant) held by The United States of America as represented by the Secretary of the Army expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Army
Grant date
Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
108
CPC classes
A61K, A61K2039/53, A61K2039/54, A61K2039/55505, A61K2039/55511